Zentalis shares jump 11.5% premarket as DENALI trial enrollment completes, FDA aligns ASPENOVA design, and insider buys $7.7M in shares.

Zentalis Pharmaceuticals (ZNTL) surged 11.50% in premarket trading following updates on its azenosertib pipeline and insider buying. The company completed Part 2a enrollment in its DENALI trial and aligned with the FDA on the Phase 3 ASPENOVA trial design, with dose confirmation and topline data expected by late 2026. A 10% owner, Walters Group, purchased $7.7 million worth of shares, signaling confidence in the refocused oncology strategy for azen.